搜索
 >  免疫检查点蛋白>B7-2 >Human B7-2 / CD86 Protein, Fc Tag

Human B7-2 / CD86 Protein, Fc Tag

分子别名(Synonym)

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

表达区间及表达系统(Source)

Human B7-2, Fc Tag (CD6-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).

Predicted N-terminus: Leu 26

蛋白结构(Molecular Characterization)

Online(Leu 26 - Pro 247) AAH40261

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 51.5 kDa. As a result of glycosylation, the protein migrates as 66-100 kDa under reducing (R) condition, and 120-140 kDa under non-reducing (NR) condition (SDS-PAGE).

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss was observed after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Human B7-2, Fc Tag (Cat. No. CD6-H5257) SDS-PAGE gel

Human B7-2, Fc Tag on SDS-PAGE under reducing (R) and no-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized Human B7-2, Fc Tag (Cat. No. CD6-H5257) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4 (Cat. No. CT4-H82E4) with a linear range of 0.1-1 μg/mL (QC tested).

点击申请Protocol

Biotinylated Human SPR

Immobilized Human B7-2, Fc Tag (Cat. No. CD6-H5257) at 2 μg/mL ( 100 μl/well ) can bind Human CTLA-4, Strep Tag (Cat. No. CT4-H5284) with a linear range of 1-20 ng/mL (QC tested).

点击申请Protocol

活性(Bioactivity)-FACS

Biotinylated Human FACS

Flow Cytometry assay shows that recombinant Human B7-2, Fc Tag (Cat.No. CD6-H5257) can bind to CD28 expressed on Jurkat E6.1. The concentration of B7-2 used is 2 μg/ml(Routinely tested).

点击申请Protocol

Biotinylated Human FACS

FACS analysis shows that the binding of Human B7-2, Fc Tag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing  anti-CD28 antibody. The concentration of B7-2 used is 2 μg/ml. The IC50 is 0.022 μg/ml (Routinely tested).

点击申请Protocol

Biotinylated Human FACS

FACS assay shows that Human B7-2, Fc Tag (Cat. No. CD6-H5257) can bind to 293T cells overexpressing human CTLA4 protein. The concentration of Human B7-2 is 3 μg/ml (Routinely tested).

点击申请Protocol

 
 

文献引用(Citations)

背景(Background)

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

 

前沿进展

货号/价格

CD6-H5257-200ug / ¥3400

CD6-H5257-1mg (500ug X 2) / ¥14400

文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-31604788(上海)
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
B7-2靶点信息
英文全称:Cluster of Differentiation 86
中文全称:分化群86
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:5详情
最高研发阶段:批准上市
查看更多信息

消息提示

请输入您的联系方式,再点击提交!

确定